MaaT Pharma
Lyon
About MaaT Pharma
MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into improving outcomes of immunotherapy in solid tumors, we have built a powerful discovery and analysis platform, GutPrint®, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $124.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: epa:MAAT
- Website: maatpharma.com
- Phone: +33 9 53 41 39 65
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/maat-pharma-94766 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.